BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3614 related articles for article (PubMed ID: 19155977)

  • 21. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival.
    Vlad G; Ho EK; Vasilescu ER; Colovai AI; Stokes MB; Markowitz GS; D'Agati VD; Cohen DJ; Ratner LE; Suciu-Foca N
    Hum Immunol; 2009 Aug; 70(8):589-94. PubMed ID: 19375470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy.
    Holt DB; Lublin DM; Phelan DL; Boslaugh SE; Gandhi SK; Huddleston CB; Saffitz JE; Canter CE
    J Heart Lung Transplant; 2007 Sep; 26(9):876-82. PubMed ID: 17845925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The acceptable reactive crossmatch (ARC), post-transplant monitoring, and their impact on kidney transplantation: a single center experience.
    Leone JP; Bowers V; Baliga R; Sanders C; LeFor W; Becker D; Thompson D; Resto-Ruiz S; Lopez-Cepero M
    Clin Transpl; 2011; ():373-9. PubMed ID: 22755434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
    Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
    Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Value of donor-specific antibody detection in first-graft renal transplant recipients with a negative complement-dependent cytotoxic crossmatch.
    Mahmoud KM; Ismail AM; Sheashaa HA; Gheith OA; Kamal MM; Ghoneim MA
    Exp Clin Transplant; 2009 Jun; 7(2):124-8. PubMed ID: 19715518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative single-bolus high-dose antithymocyte globulin as induction therapy in sensitized renal transplant recipients.
    Wang D; Wu WZ; Yang SL; Chen JH; Tan JM
    Chin Med J (Engl); 2006 Oct; 119(20):1683-8. PubMed ID: 17097014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of simultaneous kidney-pancreas transplantation with positive cross-match.
    Heilman RL; Chakkera H; Mazur M; Petrides S; Moss A; Mekeel K; Mulligan D; Reddy KS
    Transplant Proc; 2009; 41(1):303-6. PubMed ID: 19249540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts.
    Lawrence C; Willicombe M; Brookes PA; Santos-Nunez E; Bajaj R; Cook T; Roufosse C; Taube D; Warrens AN
    Transplantation; 2013 Jan; 95(2):341-6. PubMed ID: 23197178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Living donor renal transplantation in the presence of donor-specific human leukocyte antigen antibody detected by solid-phase assay.
    Phelan D; Mohanakumar T; Ramachandran S; Jendrisak MD
    Hum Immunol; 2009 Aug; 70(8):584-8. PubMed ID: 19477211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors and consequences of delayed graft function in deceased donor renal transplant patients receiving antithymocyte globulin induction.
    Patel SJ; Duhart BT; Krauss AG; Moore LW; Egidi MF; Amiri HS; Gaber LW; Gaber AO
    Transplantation; 2008 Jul; 86(2):313-20. PubMed ID: 18645496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.
    Jordan SC; Tyan D; Stablein D; McIntosh M; Rose S; Vo A; Toyoda M; Davis C; Shapiro R; Adey D; Milliner D; Graff R; Steiner R; Ciancio G; Sahney S; Light J
    J Am Soc Nephrol; 2004 Dec; 15(12):3256-62. PubMed ID: 15579530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinetics of cellular and humoral immunity in a successful case of positive crossmatch kidney transplantation: a case report.
    Tanimine N; Ide K; Yamashita M; Tanaka Y; Igarashi Y; Banshodani M; Tazawa H; Basnet NB; Doskali M; Onoe T; Tashiro H; Ohdan H
    Transplant Proc; 2011; 43(6):2411-4. PubMed ID: 21839279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac transplant outcomes in pediatric patients with pre-formed anti-human leukocyte antigen antibodies and/or positive retrospective crossmatch.
    Wright EJ; Fiser WP; Edens RE; Frazier EA; Morrow WR; Imamura M; Jaquiss RD
    J Heart Lung Transplant; 2007 Nov; 26(11):1163-9. PubMed ID: 18022083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. One year results of preoperative single bolus ATG-Fresenius induction therapy in sensitized renal transplant recipients.
    Wang D; Chen JH; Wu WZ; Yang SL; Wu GJ; Wang H; Tan JM
    Transplant Proc; 2007; 39(1):69-72. PubMed ID: 17275476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab and intravenous immune globulin for desensitization during renal transplantation.
    Vo AA; Lukovsky M; Toyoda M; Wang J; Reinsmoen NL; Lai CH; Peng A; Villicana R; Jordan SC
    N Engl J Med; 2008 Jul; 359(3):242-51. PubMed ID: 18635429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Flow cytometry crossmatch before kidney transplantation in contemporary practice: target cell utilization, results patterns, and associated long-term graft survival.
    Lentine KL; Graff RJ; Xiao H; Modanlou KA; Salvalaggio PR; Brennan DC; Pinsky BW; Burroughs TE; Schnitzler MA
    Clin Transpl; 2008; ():253-66. PubMed ID: 19708460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum flow cytometric C1q binding antibody analysis of renal recipients with low levels of sensitization.
    Ata P; Canbakan M; Kara M; Özel L; Ünal E; Titiz Mİ
    Transplant Proc; 2012; 44(6):1652-5. PubMed ID: 22841237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous immunoglobulin, HLA allele typing and HLAMatchmaker facilitate successful transplantation in highly sensitized pediatric renal allograft recipients.
    Valentini RP; Nehlsen-Cannarella SL; Gruber SA; Mattoo TK; West MS; Lang C; Imam AA
    Pediatr Transplant; 2007 Feb; 11(1):77-81. PubMed ID: 17239127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 181.